chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I contracted covid about 5 days ago from a patient despite being triple vaccinated with Pfizer a while ago; I contracted covid about 5 days ago from a patient despite being triple vaccinated with Pfizer a while ago; I contracted covid about 5 days ago from a patient despite being triple vaccinated with Pfizer a while ago; This is a spontaneous report received from a contactable reporter(s) (Physician) from medical information team. The reporter is the patient.  A 65 year-old patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) at the age of 65 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "hypertension" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 2), for Covid-19 Immunization; Bnt162b2 (Dose: 1), for Covid-19 immunization. The following information was reported: IMMUNISATION (medically significant), DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome unknown. The physician reported that: I contracted covid 5 days ago despite triple vaccination. By my own PCR my viral load is over 5000 and clinically I am not getting any better. How can I get Paxlovid asap.   The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Based on the information currently available, lack of efficacy of the suspected vaccine BNT162B2  and immunization cannot be completely excluded.
Redness and swelling around entire bicep and upper left arm. Patient mentioned  some soreness in the armpit/lymph node area.
15 minutes post vaccination,client reported having a "thick tongue",trouble swollowing.With in 5 minutes she reported feeling hot and chest flushed bright red.Epinephrine,.3ml was administered,911 was called.O2 was given when paramedics arrived(10 more minutes)with SATS @ 100,BP 120/90,chest was clear.Pt.was shakey.She went home that night,and went to MD the next day.She advided she stay home from work,and did not perscribe anything.Today, 10/29,client reports still feeling weak and having a sore throat. Advised client to see provider again today.
This spontaneous report was received from a nurse referring to unspecified number patients who are under 50 years old. On an unknown date the patients who are under 50 years old were prescribed with ZOSTAVAX, subcutaneous (strength and dose not reported). No other concomitant therapies reported. There were no known adverse effects reported for those patients. The outcome of the events were unknown. The is one of two reports received from the same reporter. Additional information has been requested.
No additional AE; RN reporting that a dose of GARDASIL9 with a labeled expiry of 5/1/2022 was administered to a patient on 5/13/2022; This spontaneous report was received from a registered nurse and referred to a 41-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 13-MAY-2022, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, 0.5 milliliter for prophylaxis (lot #T007035, expiration date: 01-MAY-2022, strength and route of administration were not provided) (expired product administered). No temperature excursion was involved. No additional adverse event (AE) was reported (no adverse event).
About 5 minutes after the injection I felt lightheaded/ presyncopal lasting about 5 seconds.  I had several more episodes of the same symptoms over the next hour. My vitals were checked  after the first episode and my pulse was 130 with blood pressure 179/99 and oxygen sat was  in the high 90?s. I was taken on a gurney to the ER. I was told my blood pressure and pulse improved a few minutes after the initial episode and I was observed for 2 hours with resolution of my symptoms.
This spontaneous report was received from a nurse refers to a unspecified patients of unknown age and gender. On an unknown date, the patients were vaccinated with doses of improperly stored PNEUMOVAX 23 (dose, frequency and route of administration were not reported, lot#L035686 with expiration date 16-FEB-2017). No adverse event was reported. This is one of several reports received from the same reporter. Additional information has been requested.
reports Right arm tingling & last 3 fingers are tingling, legs drained, malaise, chills, headache & back of neck hurts.
Date: 7/21/2021- Partial vision loss and blurry vision. Lasted about 5 minutes and resolved Date: 8/1/2021- Blackout while walking standing, complete right-sided weakness. Inability to move leg. Symptoms lasted about 3 minutes and resolved after sitting down.
DIARRHEA; VOMITING; BODY ACHES; CHILLS; TIREDNESS; HEADACHE; FLU LIKE SYMPTOMS; This spontaneous report received from a consumer concerned multiple patients. The patient's height, and weight were not reported. The patient's concurrent conditions included penicillin allergy, and non-smoker. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808982, and expiry: UNKNOWN) dose was not reported, administered on 09-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On APR-2021, the subject experienced flu like symptoms. On 09-APR-2021, the subject experienced vomiting. On 09-APR-2021, the subject experienced body aches. On 09-APR-2021, the subject experienced chills. On 09-APR-2021, the subject experienced tiredness. On 09-APR-2021, the subject experienced headache. On 13-APR-2021, the subject experienced diarrhea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from body aches, chills, tiredness, and headache on 10-APR-2021, was recovering from vomiting, and diarrhea, and the outcome of flu like symptoms was not reported. This report was non-serious. This case, from the same reporter is linked to 20210424370.
STUDENT FELL/FAINTED IN CLASS, UNRESPONSIVE INITIALLY TO TEACHER.  IN NURSE'S OFFICE COMPLAINED OF LIGHTHEADEDNESS.  A+OX3 AT 1210.  RASH TO CHEST AREA (RED, BLOTCHY)  NO ITCHING.  RECEIVED H1N1 VACCINE RIGHT UPPER ARM AT 0943 1/28/10 COMPLAINED OF HAND NUMBNESS/TIGHTNESS TO FINGERS.  RESPIRATORY WNL AND UNLABORED.  1304 BP 138/78 HR 100 TEMP 98 GIVEN 50 MG BENADRYL 20 ML PO AT 1318 STUDENT IMPROVED, STATES "FEELING BETTER" AND FINGERS TIGHT BUT NOT AS BAD.  PARENT TOOK HOME.
mom states lt leg swollen w/redness noted pt was fussy;MD advised DPH & advice;
Had the reaction of respiratory analogy for a couple weeks. Then my shortness of breath got worse and I had a saddle pulmonary embolism. With an emergency catheterization the doctors were able to remove a lot of the embolism?s and I was able to breathe better. Now I?m on Eliquis possibly for the rest of my life.
Vaccine kicked my Restless Leg Syndrome into high gear, making it impossible to sleep. Did not sleep for 2 nights in a row, until finally the reaction started to subside. Also, the vaccine gave me a minor case of hives rash. This has not subsided yet. But the RLS is NOT a minor problem, it is major, to me.
Temperature excursion with our Moderna Covid-19 vaccine; No adverse event; Temperature excursion with our Moderna Covid-19 vaccine, both monovalent and bivalent, doses were administered post excursion.; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Temperature excursion with our Moderna Covid-19 vaccine), POOR QUALITY PRODUCT ADMINISTERED (Temperature excursion with our Moderna Covid-19 vaccine, both monovalent and bivalent, doses were administered post excursion.) and NO ADVERSE EVENT (No adverse event) in an 80-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 045H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 01-Mar-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 01-Mar-2023, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Temperature excursion with our Moderna Covid-19 vaccine, both monovalent and bivalent, doses were administered post excursion.). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Temperature excursion with our Moderna Covid-19 vaccine) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Temperature excursion with our Moderna Covid-19 vaccine), POOR QUALITY PRODUCT ADMINISTERED (Temperature excursion with our Moderna Covid-19 vaccine, both monovalent and bivalent, doses were administered post excursion.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Temperature excursion with our Moderna Covid-19 vaccine) and POOR QUALITY PRODUCT ADMINISTERED (Temperature excursion with our Moderna Covid-19 vaccine, both monovalent and bivalent, doses were administered post excursion.).    The concomitant medication was not reported by reporter. The treatment medication was not reported by reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-715674 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-715674:Master case
her whole neck "broke out in hives"; It is also red; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (her whole neck "broke out in hives") and ERYTHEMA (It is also red) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21A) for COVID-19 vaccination.     The patient's past medical history included Memory disturbance (short term memory isn't good). Concurrent medical conditions included Drug allergy, Hypertension, Stroke (2 Stroke,), Drug allergy and Drug allergy.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, the patient experienced URTICARIA (her whole neck "broke out in hives") and ERYTHEMA (It is also red). At the time of the report, URTICARIA (her whole neck "broke out in hives") and ERYTHEMA (It is also red) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No concomitant medication was reported.  No treatment information was reported.
7/16/13-localized erythema at site of injection on right upper thigh. Presented to doctor clinic in late afternoon. Resolved uneventfully. Approx. 7/20, presented to ED with "sore" of left arm, no treatment.  On 7/23, presented to clinic with sores of L arm worsened, tender to touch, erythematous, "weepy".  No fever.  Culture taken.  Clindamycin initiated.
This spontaneous report was received from a medical assistant, referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant therapy, drug and allergy history were not provided. On an unknown date in October 2017, the patient was vaccinated with with an improperly stored dose of M-M-R II (recombinant human albumin (rHA)) (strength, dose, frequency, dose number and administration route were not reported) lot number M027637, expiration date 02-JUN-2018, for prophylaxis. Concomitant therapies included a properly stored sterile diluent used for reconstitution (lot number and expiration date were not provided). On an unspecified date in 2017, the vaccine was exposure to a temperature excursion; the data logger registered a temperature range between 47 Fahrenheit (F) and 77 F (54.6 F) for 2 hours. The previous temperature excursion registered was 47 F to 77 F (54.1 F) for 1 hour. No adverse effects were reported. This is one of four reports received from the same reporter.; Sender's Comments: US-009507513-1711USA009695: US-009507513-1711USA009697: US-009507513-1711USA008021:
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 63-year-old female patient who received SHINGRIX for prophylaxis. On 2nd March 2018, the patient received the 1st dose of SHINGRIX (intramuscular). In March 2018, less than a month after receiving SHINGRIX, the patient experienced injection site pain. On 19th March 2018, the outcome of the injection site pain was recovered/resolved. It was unknown if the reporter considered the injection site pain to be related to SHINGRIX. Additional information was reported as follows: The anatomical location for vaccination was left deltoid. The patient was vaccinated with the 1st dose of SHINGRIX and experienced soreness at the vaccination site, that lasted for a week. The reporter gave consent to follow up. This case was linked to case US2018214129 (2nd dose), reported by the same reporter for the same patient.
Left arm were sore and heavy feeling 5 hrs after the shot. Had chills, fever, night sweats and splitting like headache, some abdominal cramping, back pain and some shooting pain to joints around 2:00 am post shot. I was unable to get up due to lightheadedness, headaches, whole body aches and  left arm soreness. I could not move from side to side. 2 Ibufropen 250 mg taken that morning upon waking up with food and with 101.6 temp. Some off and on chest pressure, does not last long. On the second day, body sore still present, more on the left arm,  lightheaded, headches, some cramping. 2 Ibufropen taken again.
But she did have "crusting" of her lips that was "kind of annoying"; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP) from medical information team. The reporter is the patient.  A female patient received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose 1, single and administration date 24Mar2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ORAL DISCOMFORT (non-serious), outcome "recovered" (2021), described as "But she did have "crusting" of her lips that was "kind of annoying"".  Additional Information: It was reported that, the reporter was calling about the Pfizer booster shot. She was supposed to get the booster on 27Oct2021. Her last Pfizer vaccine was on the 24Mar2021, which according to her is about a 6-month period. She got struck by a car (she also referred to it as a terrible accident) and ended up in the withheld emergency room instead of the withheld hospital to get her booster shot. She ended up getting a fractured left elbow which she had to get surgery on 08Nov2021. She also has a weakened right leg that she had annoyance from "to do with the sacrum area". She says she said getting evaluated and probably won't get to a doctor until Feb because they're so busy. She doesn't know if she should get the booster shot at this time and yet she felt like she was overdue for it but she felt like she has plenty going on with these other things. She mentioned she did not really have any bad side effects from the other two Pfizer shots. But she did have "crusting" (the word was hard to understand and I had the caller repeat it which did not clarify much) of her lips that was "kind of annoying". When asked to spell the word she said before, she did not spell it and she said "but it went away, I did not report it because it went away, it wasn't so terrible you know". She adds she has to go to physical therapy and then she has to go to another doctor to be evaluated for her right leg which is weaker than before. She mentions she will not be in crowds and she doesn't have family so she'll be alone for holiday. Caller wanted to know if the booster shot is the same as the initial Pfizer shot, is it the same strength/ingredients. Caller wanted to know if she can take the booster right now with everything going on in her life.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
19 y/o male was given a dose of Menveo.  I went into the pharmacy to print a receipt and heard that he was on the floor.  Approached the patient and he was in his mother's arms, eyes rolled back, unconscious, and small jerking, seizure-like motions.  EMS was called, a code was called and the cart was retrieved after my initial assessment. I administered 1 dose of epinephrine injection (ndc 00115169449) to which he responded to immediately. He sat up and was very hot. We fanned him and sat him upright as he noticed nausea.  He vomited shortly afterwards. We cooled him off and he regained full functionality. We provided him with water and advised him to sip slowly. Emergency services arrived. His vitals were stable. Pulse and BP were normal. His skin tone regained color. He was checked for cognitive skills and passed. He was released on his own accord. He refused hospitalization.
Patient experienced chest pains post vaccination. EMS was on site and transported patient to the hospital. Patient was taken to ? Hospital, per patients request.
The patient received Pfizer .3ml (adult dose) as 1st dose, instead of the Pfizer Pedi dose.  No adverse symptoms were noticed. The family contacted and followed up on 11/11/21. The physician on staff also followed up with the patient's father.
One week later the pain in both feet returned and has not left; One week later the pain in both feet returned and has not left; headache; neck ache; fatigue; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age reported for herself that she received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulaytion:Solution for injection, Batch/Lot Number, Expiry Date: Unknown), via an unspecified route of administration on an unspecified date as dose 2, single for covid-19 immunization. The patient medical history included Covid. She received the Pfizer shot 3 months after Covid. No concomitant medications were reported. Historical vaccination included the patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number, Expiry Date: Unknown), via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunization and had muscle aches and tired. One week after 1st. shot, she started with neuropathy in both feet. Before second shot, they were a little better. When she received the 2nd shot she did mention her concern about her feet. They said that they had heard about hands not feet. The 2nd shot, she had headache, neck ache and fatigue. One week later the pain in both feet returned and had not left. Her last shot was in June. She wanted to know thoughts from Pfizer on that. The outcome of event "pain in both feet returned and had not left" was not recovered while the outcome of other events was unknown.  Information about Lot/batch number has been requested.
Patient received the first dose of the Pfizer Covid -19 vaccine on 2/23/2021. Patient tested positive for Covid-19 on 3/20/21 and developed symptoms shortly after. She was seen in the emergency room on 3/22 and scheduled to receive Regeneron Monoclonal Antibodies on 3/24. Patient received an infusion of Imdevimab + Casirivimab on 3/24. Patient received her second dose of the Pfizer Covid-19 vaccine on 4/6 although she received monoclonal antibodies within 90 days.
About 5 pm I started to feel very run down, I quickly started feeling worse and by 7 pm had a 101.5 fever and aches all over my body
delayed urticarial at site of injection, resolved within 24 hours with 1 dose of fexofenadine 180mg
Hives, high fevers (102-104f). Tylenol, ibuprofen, benadryl, and prednisone used first to combat symptoms. Hives spread to face, and then developed tightness with swallowing.  One dose of epi was given, which resolved hives and difficulty swallowing. My pcp was made aware. I have schedule my follow up appointment with my pcp.
NauseaVomiting, Syncope & SYNCOPE; FEVER; DIAPHORESIS; NAUSEA AND VOMITING
Chills, myalgia, axillary lymphadenopathy; Chills, myalgia, axillary lymphadenopathy; Chills, myalgia, axillary lymphadenopathy; This is a spontaneous report from a contactable other HCP. A 35-year-old female patient started to receive BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231), via an unspecified route of administration (anatomical location: arm right) from 09Jan2021 to 09Jan2021 at single dose for COVID-19 immunisation. Medical history was reported as none. The patient had first vaccine on 18Dec2020 to 18Dec2020 for COVID-19 immunisation. The patient's concomitant medications were not reported. On 09Jan2021, the patient experienced chills, myalgia, axillary lymphadenopathy. The patient did not received any treatment for the events. Outcome of the events was recovering.
Sept 9-15: Fever up to 104.5 for 5 days, atypical febrile seizures after fever and seizures. Rash head to toe for 3 days (1 grand mal seizure, other possible focal seizures-8 total). MD visit. Oct 11/Oct 12: fever up to 103 (with meds, about 12 focal seizures with one ended with blank stare >4 minutes. ER visit. Oct 13: fever.
Patient was given a pediatric (6-11 years) dose of the first dose of her monovalent series at 9:30AM on 03/17/2023. Patient should have been given an adult dose. Patient had no side effects and reacted WNL to receiving the injection. Patient declined to wait the recommended 20 minutes after the dose as she had an appointment. Patient departed RN's office around 9:35AM with no s/sx and no complaints.
high fever, irritability, WBC 20,000, 12% bands, 46% segs;admit to hosp poss sepsis, poss rxn to DTP vax, anemia;
Pt received Abrysvo on 10/7/23 Lot # HF5024 intramuscularly into the left arm. She again received a 2nd RSV shot Arexvy lot # LL942 intramuscularly into the left arm on 11/7/23. Pt discovered the mistake today while at her doctor's appointment and called the pharmacy. She reports having experienced no adverse side effects.
On 3/10/2021 the patient presented to the ED with chest pain and fatigue. The patient was found to be hyponatremic. His sodium was repleted  and his BP medications were adjusted. Per EUA, hospitalizations must be reported due to recent vaccine administration. This hospitalization appears not to be related to the vaccine.
blood clots; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE, MANUFACTURER UNKNOWN), for Covid-19 Immunization; Covid-19 vaccine (DOSE 2, SINGLE, MANUFACTURER UNKNOWN), for Covid-19 Immunization. The following information was reported: THROMBOSIS (hospitalization, medically significant), outcome "unknown", described as "blood clots".  Clinical course: Patient wanted to know if it is recommended that she get the 2nd booster dose of Pfizer-Biontech Covid vaccine given her history of getting blood clots and being hospitalized after getting previous the doses.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021229915 Same patient and drug, different event separated in time;
Pt says hes gotten Schamberg's disease after getting the booster about 30 days after getting booster